Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...

Bristol Myers Squibb (BMY) closed at $47.51 in the latest trading session, marking a +2.64% move from the prior day.

Bristol-Myers Squibb is running a rigorous Phase 2/3 clinical trial on ozanimod, aiming to help children with moderate to severe ulcerative colitis who haven’t responded to conventional treatments.

The stock's rise snapped a four-day losing streak.

In total, there are about 50 student volunteers, along with an additional 350 volunteers registered to work on an ad hoc ...

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, ...

The market, which was valued at $0.85 billion in 2024, is projected to grow to $0.91 billion in 2025, representing a compound annual growth rate CAGR of 7.2%. The growth during this historic period ...

BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Galapagos announces leadership transition. European biotechnology company Galapagos completed a significant leadership ...